Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Lowered by Wall Street Zen

Fulcrum Therapeutics (NASDAQ:FULC) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other equities research analysts also recently commented on FULC. Royal Bank Of Canada boosted their target price on shares of Fulcrum Therapeutics from $4.00 to $5.00 and gave the company a “sector perform” rating in a research note on Wednesday, July 30th. Piper Sandler restated an “overweight” rating and issued a $9.00 target price (up previously from $6.00) on shares of Fulcrum Therapeutics in a research note on Thursday, May 29th. Leerink Partnrs upgraded shares of Fulcrum Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 23rd. Cantor Fitzgerald upgraded shares of Fulcrum Therapeutics from a “neutral” rating to an “overweight” rating and set a $10.00 target price on the stock in a research note on Thursday, May 15th. Finally, Leerink Partners upgraded shares of Fulcrum Therapeutics from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $4.00 to $12.00 in a research note on Friday, May 23rd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Fulcrum Therapeutics currently has an average rating of “Hold” and a consensus target price of $7.57.

Fulcrum Therapeutics Price Performance

FULC opened at $6.49 on Friday. Fulcrum Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $10.13. The firm’s fifty day moving average price is $7.18 and its two-hundred day moving average price is $5.09. The company has a market capitalization of $351.04 million, a P/E ratio of -5.32 and a beta of 2.47.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings results on Tuesday, July 29th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. On average, equities research analysts expect that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new position in Fulcrum Therapeutics during the 4th quarter worth about $38,000. Jump Financial LLC bought a new stake in Fulcrum Therapeutics during the 1st quarter worth about $30,000. Brooklyn Investment Group raised its holdings in Fulcrum Therapeutics by 209.7% during the 1st quarter. Brooklyn Investment Group now owns 12,190 shares of the company’s stock worth $35,000 after purchasing an additional 8,254 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its holdings in Fulcrum Therapeutics by 26.1% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 12,943 shares of the company’s stock worth $89,000 after purchasing an additional 2,677 shares during the last quarter. Finally, Los Angeles Capital Management LLC bought a new stake in Fulcrum Therapeutics during the 2nd quarter worth about $93,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.